Trial Profile
To assess bone health by phalangeal quantitative ultrasound and by dual energy X-ray absorptiometry in aromatase inhibitor treated breast cancer patients receiving Denosumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Apr 2017
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Bone disorders; Breast cancer
- Focus Therapeutic Use
- 03 Apr 2017 New trial record
- 22 Mar 2017 Results published in the Journal of Endocrinological Investigation